Sequence: R8 (RRRRRRRR)
| Experiment Id | EXP002541 |
|---|---|
| Paper | A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine |
| Peptide | STR-R8 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 10 mol% STR-R8 (surface) |
| Rna Concentration | 400 nM (typical; also 200 nM when SOR=5 µM) |
| Mixing Ratio | siRNA:drug molar ratio 1:25 (0.4 µM siRNA : 10 µM SOR); siRNA/lipid ~1:500; PEI N/P=0.5 core |
| Formulation Format | Lipid nanoparticles (LNPs); siRNA/PEI core + lipid film hydration; sonication; ultrafiltration |
| Formulation Components | YSK05/EPC/cholesterol/STR-R8 = 4:3:2:1 (molar ratio); siRNA complexed with PEI (N/P=0.5); SOR co-loaded |
| Size Nm | 180.00 |
| Zeta Mv | 49.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HepG2 (human HCC); Hepa 1-6 (mouse HCC); HeLa; FL83B (normal mouse hepatocytes) |
| Animal Model | |
| Administration Route | |
| Output Type | MK mRNA knockdown EC50 (qRT-PCR) + cytotoxicity readouts |
| Output Value | Optimized formulation reduced MK knockdown EC50 to ~30 nM in HepG2; nonselective uptake/cytotoxicity higher in FL83B vs HepG2 (uptake ~5.26×; viability FL83B ~8% vs HepG2 ~25% at SOR 10 µM + MK-siRNA 400 nM) |
| Output Units | |
| Output Notes | FACS + CLSM uptake; qRT-PCR MK knockdown; MTT viability. STR-R8 improves uptake and is linked to endosomal escape; YSK05 described as pH-sensitive with endosomal escape properties. |
| Toxicity Notes | Nonselective: higher uptake and cytotoxicity in normal FL83B than HepG2; empty carrier toxicity reduced after optimization (empty LNP viability ~86%). |
| Curation Notes |